New treatment for amblyopia based on rules of synaptic plasticity: a randomized clinical trial

Author(s):  
Xin Huang ◽  
Huika Xia ◽  
Qi Zhang ◽  
Colin Blakemore ◽  
Yan Nan ◽  
...  
2007 ◽  
Vol 25 (31) ◽  
pp. 5019-5023 ◽  
Author(s):  
Boris Freidlin ◽  
Edward L. Korn ◽  
Stephen L. George ◽  
Robert Gray

The randomized clinical trial (RCT) is the gold standard for definitive evaluation of new therapies. RCTs designed to show that the therapeutic efficacy of a new therapy is not unacceptably inferior to that of standard therapy are called noninferiority trials. Traditionally, noninferiority trials have required very large sample sizes. Sometimes, a new treatment regimen with a favorable toxicity and/or tolerability profile is also expected to have some modest improvement in efficacy. In such specialized settings we describe a hybrid trial-design approach that requires a dramatically smaller sample size than that of a standard noninferiority design. This hybrid design can naturally incorporate a formal test of superiority as well as noninferiority.


2002 ◽  
Vol 89 (2) ◽  
pp. 154-157 ◽  
Author(s):  
F. F Palazzo ◽  
D. L Francis ◽  
M. A Clifton

2001 ◽  
Vol 120 (5) ◽  
pp. A453-A453 ◽  
Author(s):  
B SHEN ◽  
J ACHKAR ◽  
B LASHNER ◽  
A ORMSBY ◽  
F REMZI ◽  
...  

2017 ◽  
Vol 64 (3) ◽  
pp. 247-260 ◽  
Author(s):  
Andrew S. McClintock ◽  
Matthew R. Perlman ◽  
Shannon M. McCarrick ◽  
Timothy Anderson ◽  
Lina Himawan

Sign in / Sign up

Export Citation Format

Share Document